Benefit-risk modeling of medicinal products: Methods and applications

Benefit-Risk Assessment in Pharmaceutical Research and Development

Volumn , Issue , 2013, Pages 59-96

  Phillips, Lawrence D ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123459790     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Eichler, H.-G., Abadie, E., Raine, J.M., and Salmonson, T. 2009. Safe drugs and the cost of good intentions. New England Journal of Medicine 360: 1378-1380.
2. Phillips, L.D. 1993. Decision theory and its relevance to pharmaceutical medicine. In Textbook of pharmaceutical medicine, ed. R.D. Mann, M.D. Rawlins, and R.M. Auty, 247-255. Carnforth, Lancashire: Parthenon Publishing Group.
3. CIOMS IV. 1999. Benefit-risk balance for marketed drugs. Evaluating safety signals. Geneva: Council for International Organizations of Medical Sciences.
4. Mussen, F., Salek, S., and Walker, S. 2007. A quantitative approach to benefit-risk assessment of medicines. Part 1. The development of a new model using multi-criteria decision analysis. Pharmacoepidemiology and Drug Safety 16: S2-S15.
5. Mussen, F., Salek, S., and Walker, S. 2009. Benefit-risk appraisal of medicines: A systematic approach to decision-making. Chichester: John Wiley & Sons.
6. European Medicines Agency. 2012. Benefit-risk methodology project: Report on risk perception study module, 1-68. London. www.ema.europa.eu, Special topics, Benefit-risk methodology.
7. Wallsten, T., Budescu, D., and Zwick, R. 1993. Comparing the calibration and coherence of numerical and verbal probability judgments. Management Science 39: 176-190.
8. Kahneman, D. 2011. Thinking, fast and slow. London: Allen Lane.
9. Raiffa, H. 1968. Decision analysis. Reading, MA: Addison-Wesley.
10. Keeney, R., and Raiffa, H. 1976. Decisions with multiple objectives: Preferences and value tradeoffs. New York: John Wiley. (Republished 1993, Cambridge University Press.)
11. Weinstein, M., Torrance, G., and McGuire, A. 2009. QALYs: The basics. Value in Health 12: S5-S9.
12. Meehl, P. 1996. Clinical versus statistical prediction: A theoretical analysis and a review of the evidence. Northvale, NJ: Jason Aronson. (Original 1954 edition, University of Minnesota Press.)
13. Grove, W., and Meehl, P. 1996. Comparative efficiency of informal (subjective, impressionistic) and formal (mechanical, algorithmic) prediction procedures: The clinical-statistical controversy. Psychology, Public Policy, and Law 2: 293-323.
14. European Medicines Agency. 2009. Work package 1 report: Description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network, 23. London. www.ema.europa.eu, Special topics, Benefit-risk methodology.
15. European Medicines Agency. 2010. Guidance document: Day 80 critical assessment report.
16. Guo, J., Pandey, S., Doyle, J., Bian, B., Lis, Y., and Raisch, D. 2010. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy: Report of the ISPOR risk-benefit management working group. Value Health 13: 657-666.
17. Holden, W. 2003. Benefit-risk analysis: A brief review and proposed quantitative approaches. Drug Safety 26: 853-862.
18. European Medicines Agency. 2010. Work package 2 report: Applicability of current tools and processes for regulatory benefit-risk assessment, 33. London. www.ema.europa.eu, Special topics, Benefit-risk methodology.
19. Shahrul M., et al. 2012. Benefit-risk integration and representation. London: PROTECT Consortium.
20. European Medicines Agency. 2011. Work package 3 report: Field tests, 29. London. www.ema.europa.eu, Special topics, Benefit-risk methodology.
21. Belton, V., and Stewart, T. 2002. Multiple criteria decision analysis: An integrated approach. Boston: Kluwer Academic Publishers.
22. Dodgson, J., Spackman, M., Pearman, A., and Phillips, L. 2000. Multi-criteria analysis: A manual. London: Department of the Environment, Transport and the Regions. (Republished 2009 by the Department for Communities and Local Government.)
23. Ramsey, F. 1926. Truth and probability. In The foundations of mathematics and other logical essays, ed. R. Braithwaite, 156-198. London: Kegan, Paul, Trench, Trubner & Co.
24. von Neumann, J., and Morgenstern, O. 1947. Theory of games and economic behavior. 2nd ed. Princeton, NJ: Princeton University Press.
25. Savage, L. 1954. The foundations of statistics. New York: Wiley. (2nd ed., 1972, New York: Dover Publications.)
26. Raiffa, H., and Schlaifer, R. 1961. Applied statistical decision theory. Cambridge, MA: Harvard University Press.
27. Howard, R. 1966. Decision analysis: Applied decision theory. In Proceedings of the Fourth International Conference on Operational Research, ed. D. Hertz and J. Melese, 55-71. New York: Wiley-Interscience.
28. Hammond, J., Keeney, R., and Raiffa, H. 1999. Smart choices: A practical guide to making better decisions. Boston: Harvard University Press.
29. Phillips, L. 2007. Decision conferencing. In Advances in decision analysis: From foundations to applications, ed. W. Edwards, R. Miles, and D. von Winterfeldt, 375-399. Cambridge: Cambridge University Press.
30. Franco, L., and Montibeller, G. 2010. Facilitated modelling in operational research. European Journal of Operational Research 205: 489-400.
31. http://en.wikipedia.org/wiki/Hiview3.
32. http://www.visadecisions.com/.
33. http://www.logicaldecisions.com/.
34. http://www.m-macbeth.com/en/m-home.html.
35. Walker, S., Phillips, L., and Cone, M. 2006. Benefit-risk assessment model for medicines: Developing a structured approach to decision making. Epsom: Centre for Medicines Research International, Institute for Regulatory Science.
36. Felli, J., Noel, R., and Cavazzoni, P. 2009. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives. Medical Decision Making 29: 104-115.
37. Alexiev, V. 2010. Modelling the balance of clinical efficacy and safety of drugs in the context of regulatory evaluation for marketing authorization. London: London School of Economics and Political Science.
38. Ali-Basah, C. 2010. Modelling the balance of favourable and unfavourable effects of a drug in the presence of uncertainty for a regulatory environment: The case for Cimzia using multi criteria decision analysis (MCDA) and Monte Carlo simulation. London: London School of Economics and Political Science.
39. Kochanowska, E. 2010. Modelling the balance of favourable and unfavourable effects of a drug in the presence of uncertainty: The case of Acomplia with the use of multi-criteria decision analysis. London: London School of Economics and Political Science.
40. Thoi, D. 2010. Quantitative risk-benefit analysis of Sutent using a Markov model. London: London School of Economics and Political Science.
41. European Medicines Agency. 2012. Work package 4 report: Benefit-risk tools and processes, 20. London. www.ema.europa.eu, Special topics, Benefit-risk methodology.
42. Lichtenstein, S., and Slovic, P., eds. 2006. The construction of preference. New York: Cambridge.
43. Phillips, L. 1984. A theory of requisite decision models. Acta Psychologica 56: 29-48.
44. Keeney, R. 1992. Value-focused thinking: A path to creative decisionmaking. Cambridge, MA: Harvard University Press.
45. Verghese, A. 2009. Cutting for stone. New York: Vintage Books.
46. Payer, L. 1996. Medicine and culture. New York: Henry Holt and Company.
47. Miller, G. 1956. The magical number seven, plus or minus two: Some limits on our capacity for processing information. Psychological Review 63: 81-97.
48. Edwards, W. 1968. Conservatism in human information processing. In Formal representations of human judgment, ed. B. Kleinmuntz, 17-52. New York: Wiley.
49. Edwards, W., Phillips, L., Hays, W., and Goodman, B. 1968. Probabilistic information processing systems: Design and evaluation. IEEE Transactions on Systems Science and Cybernetics SSR-4; 248-265.
50. Phillips, L., Hays, W., and Edwards, W. 1966. Conservatism in complex probabilistic inference. IEEE Transactions on Human Factors in Electronics HFE-7: 7-18.